Please login or register first to view this content.
Ophthalmic Disorders Resource Center
Drug Monographs
Click on the subsection below to see prescribing information
NEWS & FEATURES
FDA to Review Novel Cyclosporine Ophthalmic Solution for Dry Eye Disease
CDC Report Warns of Serious Ocular Complications With Monkeypox
Aflibercept Granted Priority Review for Retinopathy of Prematurity
September 2022: Notable Drug Approvals
Omlonti Approved for Open-Angle Glaucoma, Ocular Hypertension
Update on Availability of Cimerli, a Biosimilar to Lucentis
August 2022: Notable Drug Approvals
FDA to Review Perfluorohexyloctane Ophthalmic Solution for Dry Eye Disease
FDA Clears At-Home Visual Acuity Testing System
Deoxycytidine Kinase Inhibitor Designated Orphan Drug for Optic Neuritis
Tarcocimab Improves Vision in Patients With Macular Edema Due to Retinal Vein Occlusion
Cimerli Approved as Interchangeable Biosimilar to Lucentis
FDA Drafts Guidance on Patient Labeling Information for LASIK Devices
FDA Approves Small Aperture Intraocular Lens for Cataract Patients
Intravitreal Pegcetacoplan Gets Priority Review for Geographic Atrophy
Diabetic Macular Edema Outcomes Compared for Aflibercept, Bevacizumab
June 2022 Recap: Drug Pipeline Updates
Aflibercept 16-Week Dosing Regimen for Diabetic Retinopathy Under Review